Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Discussing Mandatory Reporting System for Unstable Drug Supplies
August 30, 2021
- 500,000 of Suspended Moderna Vaccine Doses Already Used: Kono
August 30, 2021
- Govt Not Planning to Resume Active HPV Vaccine Recommendation before October: Minister
August 30, 2021
- MHLW Health Policy Bureau Seeks FY2022 Budget to Set Up Manufacturing Regime for Stable Supplies
August 27, 2021
- MHLW Health Service Bureau Seeks 468.6 Billion Yen in FY2022, 46% Rise for Infectious Disease Measures
August 27, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- MHLW to Request a Record 34 Trillion Yen General Account Budget for FY2022
August 27, 2021
- MHLW Pharma Safety Bureau Seeks 246 Million Yen to Shake Off Public Distrust in Generics: FY2022 Budget Request
August 27, 2021
- MHLW Won’t Recall Moderna Vaccine Vials for Now
August 26, 2021
- Japan Approves Forxiga for CKD, Rinvoq’s Atopic Dermatitis Use and More
August 26, 2021
- Trade Groups Urges New Reimbursement Fee Evaluation for SaMD
August 26, 2021
- Takeda’s Pevonedistat Gets 1st Sakigake Tag under PMD Law
August 26, 2021
- COVID-19 Antibody Cocktail to Be Made Available for Outpatients Too: Minister
August 25, 2021
- Orphan Status Granted to Fenfluramine, Asciminib, Vosoritide
August 25, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- PAFSC to Review Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug and More
August 24, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
- MHLW to Seek Budget to Boost GMP Inspections to Secure Trust in Generics: FY2022 Request
August 23, 2021
- New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
August 23, 2021
- Sharp Drop in Suspected Violations Seen in FY2020 Drug Promotion, but Comparison Difficult due to COVID-19: MHLW
August 23, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…